22 January 2021>: Original Paper
Effect of Everolimus with Low-Dose Tacrolimus on Development of New-Onset Diabetes After Transplantation and Allograft Function in Kidney Transplantation: A Multicenter, Open-Label, Randomized Trial
Hyung Duk Kim 1BEF , Ji-Yeun Chang 1CDE , Byung Ha Chung 1AB , Chan-Duck Kim 2B , Sang-Ho Lee 3B , Yeong Hoon Kim 4B , Chul Woo Yang 1ADG*DOI: 10.12659/AOT.927984
Ann Transplant 2021; 26:e927984
Supplementary Table 3 Comparison of the oral glucose tolerance test.
EVL group (n=38) | TAC group (n=39) | P-value | |
---|---|---|---|
Baseline | 97.47±9.48 | 98.87±10.11 | 0.5333 |
12 months | 96.79±13.44 | 100.18±15.53 | 0.2493 |
Mean change from baseline | −0.68±11.26 | 1.31±11.09 | 0.6057 |
p-value | 0.3248 | 0.9693 | |
Baseline | 121.24±30.12 | 117.00±32.71 | 0.4538 |
12 months | 117.24±27.49 | 117.46±38.21 | 0.5242 |
Mean change from baseline | −4.00±24.14 | 0.46±35.28 | 0.5185 |
p-value | 0.3138 | 0.9353 | |
OGTT – oral glucose tolerance test; PP2 – 2 hours post-prandial. |